REG - IXICO plc - Further Validation of IXICO’s AI Imaging Platform

IXICOAnnouncement

12/02/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250212:nRSL7606Wa&default-theme=true

RNS Number : 7606W  IXICO plc  12 February 2025

 

IXICO plc

("IXICO" or the "Company")

 

Huntington's Disease consortium further validates

IXICO's AI imaging platform

 

Sets new standards of analysis in neurological disease and presents additional
future revenue opportunities

 

12 February 2025 - London, UK. IXICO plc (AIM: IXI, "IXICO" or "the Company")
a global leader in neuroscience imaging, using its AI-driven platform to help
advance drug development in neurological disorders, today announces, the
generation of further evidence verifying the superiority of the 'IXIQ.Ai'
analysis platform in the development and validation of imaging biomarkers for
Huntington's Disease (HD),  in conjunction with the Huntington's Disease
Imaging Harmonisation ("HD-IH") consortium.

 

HD-IH has passed a significant milestone in HD research by successfully
completing the analysis of over 6,000 MRI datasets within the HD-IH framework;
the largest image HD dataset of its kind.  Using the HD-IH data, IXICO has
generated updated HD-Integrated Staging System (HD-ISS) 'cut off values', used
to guide disease diagnosis, severity and treatment, in the caudate and putamen
areas of the brain.

 

Applying a proprietary deep learning regional segmentation algorithm IXIQ.Ai
was able to establish high quality brain measurements to characterise
volumetric changes across the HD-ISS Stages, providing deeper insights into
the progression of HD.  Additionally, IXICO is working, in collaboration with
Key Opinion Leaders, to provide further evidence for the use of brain volume
changes measured with IXIQ.Ai as an alternative trial endpoint to traditional
clinical outcomes (surrogate endpoint).

 

The validation advances HD understanding, provides enhanced tools for imaging
biomarkers to the biopharma industry and, further evidences the beneficial use
of IXIQ.Ai in neurodegenerative disease clinical trials.  Such progress has
enabled IXICO to expand its clinical trial biomarker analysis offering and
presents future revenue opportunities, both within the HD-IH consortium and
with additional commercial biopharma partners.

 

Robin Wolz, Chief Scientific Officer, IXICO, commented: "HD-ISS provides an
evidence based biomarker-based framework for the biological definition of
HD.  The completion of HD-ISS staging cut-off points is an important
achievement in the HD-IH consortium. The relevant brain volume measures in a
highly accurate and automated tool like IXIQ.Ai allows reliable and robust
implementation of the staging system in HD clinical trials. With this major
milestone, we will focus with our partners to put those measures into clinical
trial use and build further evidence towards the use of brain volumetric
measures as surrogate endpoints."

 

Cristina Sampaio, Chief Medical Officer, CHDI Management, Inc., commented,
"It's exciting to see the HD-IH consortium reach this critical milestone in
the imaging harmonization plan. The HD-ISS caudate and putamen volume cut-offs
are specific for each analytical software platform, and seeing these values
become available for the IXIQ.Ai platform is a huge step toward facilitating
the generalization of the HD-ISS in defining clinical trial populations."

 

Ends

 

This announcement contains inside information as stipulated under the retained
EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR")
which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.
The information is disclosed in accordance with the Company's obligations
under Article 17 of the UK MAR.

 

Further information:

 

 IXICO plc                                                                         +44 (0) 20 3763 7499
 Bram Goorden, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and                          +44 (0) 20 7220 0500

 Sole Broker)
 Giles Balleny / Dan Hodkinson (Corporate Finance)

 Nigel Birks/Harriet Ward (Corporate Broking)

 Michael F Johnson / Tamar Cranford Smith (Sales)

 

About HD-IH

The Huntington's Disease Imaging Harmonisation ("HD-IH") consortium is a
collaborative initiative focused on harmonising imaging analyses to better
understand structural brain changes in Huntington's disease. By leveraging
advanced imaging techniques and AI-driven analysis, HD-IH aims to accelerate
the development of effective treatments for HD.

 

HD-IH is a partnership between IXICO, the CHDI Foundation, uniQure, PTC
Therapeutics, Asklepios BioPharmaceutical, and newest member Wave Life
Sciences, who joined in July 2024.  Over the past year, the expanding
partnership has made significant progress in applying IXIQ.Ai to more than
6,000 MRI scans available to the consortium and generating the data required
to demonstrate the utility of biomarker measurements as clinical trial
endpoints.

 

About IXICO www.IXICO.com (http://www.IXICO.com)

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

About IXIQ.Ai

IXIQ.Ai is a proprietary neuroimaging technology developed by IXICO for brain
region analysis using AI to measure  brain segmentation.  The technology
provides IXICO research scientists with an agile way to efficiently and
rapidly deploy imaging analysis solutions and support clinical decision making
for its partners, including critical insights into patient eligibility and
drug efficacy.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPUPCPUPAPGG